Radiation plus drug cocktail targets tough colorectal cancer
NCT ID NCT07535632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding targeted radiation (SBRT) and an immunotherapy drug (sintilimab) to standard chemotherapy (TAS-102) and bevacizumab can help people with recurrent metastatic colorectal cancer live longer without their cancer growing. The study will enroll 58 adults who have already tried at least two prior treatments. Participants are randomly assigned to receive either the new combination or standard third-line therapy. The main goal is to see if the new approach delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Stereotactic body radiation therapy (SBRT), sintilimab, bevacizumab, and trifluridine/tipiracil (TAS-102)
- What this could lead to
- If successful, this combination could offer a new third-line treatment option that slows cancer growth and improves survival for patients with advanced colorectal cancer.
- What could go wrong
- This is a small, early-phase trial (58 people) with no results yet. The combination may cause significant side effects or fail to improve outcomes over standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- Peer power: could community education boost cancer screening?
- AI eye for colonoscopy: could software catch what doctors miss?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?